1 Name
(1) This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 11).
(2) This Instrument may also be cited as PB 119 of 2021.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 December 2021 | 1 December 2021 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 84AAA(2) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
[1] Schedule 1, omit entry for Dalteparin
[2] Schedule 1, after entry for Lamotrigine in the form Tablet 200 mg
insert:
Lanadelumab | Injection 300 mg in 2 mL single use pre-filled syringe | 20 | 1 | 5 | |
[3] Schedule 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 1 g per sachet
omit:
[4] Schedule 1, entry for Ribavirin
insert as first entry:
[5] Schedule 1, after entry for Riluzole
insert:
Ripretinib | Tablet 50 mg | 20 | 90 | 1 | |
[6] Schedule 1, entry for Venetoclax
substitute:
Venetoclax | Tablet 100 mg | 20 | 120 | 2 | |
| | 20 | 120 | 4 | |
| | 20 | 120 | 5 | |
